Author

Jay M. Mei

Observed names: J M Mei, J Mei, J. M. Mei, J. Mei, J.M. Mei, Jay Mei

Observed institutions: National Institutes of Health, Frederick National Laboratory for Cancer Research, National Cancer Institute, Center for Cancer Research, Celgene (United States), Antengene Corporation Limited (China), Janssen Research & Development (United States)

ORCID: 0009-0000-6211-4175

Observed ORCID: 0009-0000-6211-4175

OpenAlex ID: A5001996286

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

2012 · Antonio Palumbo, Roman Hajek, et al. · New England Journal of Medicine · 742

PDF

Proline oxidase, encoded by p53-induced gene-6, catalyzes the generation of proline-dependent reactive oxygen species.

2001 · S P Donald, X Y Sun, et al. · PubMed · 283

Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

2016 · J. R. Brown, W. A. Harb, et al. · Haematologica · 81

PDF

Cloning, Expression, and Functional Characterization of Human Cyclooxygenase-1 Splicing Variants: Evidence for Intron 1 Retention

2005 · Ning Qin, Sui-Po Zhang, et al. · Journal of Pharmacology and Experimental Therapeutics · 77

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

2015 · Eytan M. Stein, Courtney DiNardo, et al. · Blood · 72

Differential expression of prostaglandin endoperoxide H synthase-2 and formation of activated β-catenin–LEF-1 transcription complex in mouse colonic epithelial cells contrasting in Apc

1999 · J.M. Mei, N.G. Hord, et al. · Carcinogenesis · 56

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone In Patients ≥ 65 Years with Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide Vs Fixed-Duration Regimens

2010 · Antonio Palumbo, Michel Delforge, et al. · Blood · 55

Matrix metalloproteinase(s) mediate(s) NO-induced dissociation of beta-catenin from membrane bound E-cadherin and formation of nuclear beta-catenin/LEF-1 complex

2002 · J. M. Mei · Carcinogenesis · 54

A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial

2013 · Jian Hou, Xin Du, et al. · Journal of Hematology & Oncology · 48

PDF

A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma.

2009 · Antonio Palumbo, Meletios A. Dimopoulos, et al. · Blood · 48

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

2013 · Jennifer R. Brown, Wael A. Harb, et al. · Blood · 45

Expression of prostaglandin endoperoxide H synthase‐2 induced by nitric oxide in conditionally immortalized murine colonic epithelial cells

2000 · Jay M. Mei, Norman G. Hord, et al. · The FASEB Journal · 44

Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial

2013 · Meletios A. Dimopoulos, Antonio Palumbo, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 38

(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors with Broad Antiproliferative Activity against Tumor Cells

2005 · Chih Y. Ho, Donald W. Ludovici, et al. · Journal of Medicinal Chemistry · 35

N-glucuronidation of the Platelet-derived Growth Factor Receptor Tyrosine Kinase Inhibitor 6,7-(dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)-(3-fluoro-phenyl)-amine by Human Udp-glucuronosyltransferases

2006 · Z. Yan, G.W. Caldwell, et al. · Drug Metabolism and Disposition · 32

Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older.

2011 · A. P. Palumbo, M. Delforge, et al. · Journal of Clinical Oncology · 27

ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation

2024 · Hui Yuwen, Huajing Wang, et al. · Cancer Research · 20

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65–75 Yrs Enrolled in MM-015

2011 · Antonio Palumbo, Zdenek Adam, et al. · Blood · 20

Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*

2016 · Clemens M. Wendtner, Michael Hallek, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 19

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial

2016 · A Bühler, C-M Wendtner, et al. · Blood Cancer Journal · 18

PDF

Gene Expression Analysis for High Throughput Screening Applications

2004 · Albert Pinhasov, Jay Mei, et al. · Combinatorial Chemistry & High Throughput Screening · 17

Population Pharmacokinetics and Exposure Response Assessment of CC‐292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia

2017 · Yan Li, Francisco Ramírez‐Valle, et al. · The Journal of Clinical Pharmacology · 15

PDF

Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment

2015 · Dao-bin Zhou, Li Yu, et al. · International Journal of Hematology · 13

Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis

2005 · Michael R. D'Andrea, Jay M. Mei, et al. · Molecular Cancer Therapeutics · 13

PDF

Multiplexed RT- PCR for High Throughput Screening Applications

2004 · Derrick Maley, Jay Mei, et al. · Combinatorial Chemistry & High Throughput Screening · 13

Works count: 97

Citation count: 1,969

H-index: 19

I10-index: 25